Lifecore Biomedical, Inc. Share Price

Equities

LFCR

US5147661046

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
6.595 USD -0.68% Intraday chart for Lifecore Biomedical, Inc. -1.42% +6.54%
Sales 2024 * 126M 10.07B Sales 2025 * 145M 11.6B Capitalization 201M 16.07B
Net income 2024 * 6M 479M Net income 2025 * 18M 1.44B EV / Sales 2024 * 1.6 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
30 x
P/E ratio 2025 *
11.4 x
Employees 459
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.68%
1 week-1.42%
Current month+24.20%
1 month+24.20%
3 months-0.68%
6 months-6.19%
Current year+6.54%
More quotes
1 week
6.10
Extreme 6.1
6.75
1 month
5.23
Extreme 5.23
6.75
Current year
4.50
Extreme 4.5
8.90
1 year
4.13
Extreme 4.13
11.46
3 years
1.52
Extreme 1.52
12.88
5 years
1.52
Extreme 1.52
12.88
10 years
1.52
Extreme 1.52
15.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 31/05/17
Director of Finance/CFO 60 17/01/21
Chief Operating Officer - 31/12/19
Members of the board TitleAgeSince
Director/Board Member 77 11/10/18
Director/Board Member 64 13/10/20
Director/Board Member 66 04/08/19
More insiders
Date Price Change Volume
26/04/24 6.595 -0.68% 110,906
25/04/24 6.64 +4.90% 256,407
24/04/24 6.33 -1.86% 105,089
23/04/24 6.45 +2.54% 136,987
22/04/24 6.29 -5.98% 169,821

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.595 USD
Average target price
6 USD
Spread / Average Target
-9.02%
Consensus